|
Actionable targets in recurrent bile duct and pancreatic cancer in a prospective cohort of patients evaluated by whole exome sequencing and SNP array analysis. |
|
Ida Elisabeth Viller Tuxen |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Novartis; Pfizer; Roche Pharma AG |
Consulting or Advisory Role - Pfizer |
Travel, Accommodations, Expenses - Novartis; Pfizer; Roche Pharma AG |
|
|
Research Funding - Roche Pharma AG |
|
|
No Relationships to Disclose |